Roberto H Nussenzveig
Overview
Explore the profile of Roberto H Nussenzveig including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
396
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Swami U, Sayegh N, Jo Y, Haaland B, McFarland T, Nussenzveig R, et al.
Mol Cancer Ther
. 2022 Oct;
21(12):1857-1861.
PMID: 36198026
Approximately 20% of men with metastatic castration-sensitive prostate cancer (mCSPC) progress within 1 year of treatment, and biomarkers to identify them up front are lacking. In a randomized phase III...
2.
Swami U, Zimmerman R, Nussenzveig R, Hernandez E, Jo Y, Sayegh N, et al.
Front Oncol
. 2022 Oct;
12:966534.
PMID: 36185208
-mutated prostate cancer has been shown to be less responsive to poly (ADP-ribose) polymerase (PARP) inhibitors as compared to -mutated prostate cancer. The reason for this differential response is not...
3.
Swami U, Graf R, Nussenzveig R, Fisher V, Tukachinsky H, Schrock A, et al.
Clin Cancer Res
. 2022 Sep;
28(22):4917-4925.
PMID: 36088616
Purpose: Intensification of androgen deprivation therapy (ADT) with either docetaxel or androgen receptor axis-targeted therapies (ARAT) are the current standard of care for patients with metastatic castration-sensitive prostate cancer (mCSPC)....
4.
Sayegh N, Tripathi N, Nussenzveig R, Mathew Thomas V, Tandar C, Goel D, et al.
Eur Urol Focus
. 2022 Jul;
9(1):106-109.
PMID: 35835693
Androgen receptor axis-targeted therapies (ARATs; androgen receptor or androgen synthesis inhibitors) have been approved for the treatment of patients with metastatic castration-sensitive and castration-resistant prostate cancer (mCSPC and mCRPC) on...
5.
Lin E, Hahn A, Nussenzveig R, Wesolowski S, Sayegh N, Maughan B, et al.
Oncologist
. 2021 Jun;
26(9):751-760.
PMID: 34157173
Purpose: Progression from metastatic castration-sensitive prostate cancer (mCSPC) to a castration-resistant (mCRPC) state heralds the lethal phenotype of prostate cancer. Identifying genomic alterations associated with mCRPC may help find new...
6.
Swami U, Nussenzveig R, Agarwal N
Clin Cancer Res
. 2020 Aug;
26(19):5059-5061.
PMID: 32759359
In the CheckMate 275 study, composite biomarkers appear to better predict response to immunotherapy over individual ones. Nevertheless, the path forward needs consensus guidelines for biomarker interpretation. Thereafter, prospective validation...
7.
Ledet E, Lilly M, Sonpavde G, Lin E, Nussenzveig R, Barata P, et al.
Oncologist
. 2020 Apr;
25(4):327-333.
PMID: 32297439
Background: Somatic alterations in circulating tumor DNA (ctDNA) may be associated with treatment response or prognosis in prostate cancer (PCa). The goal was to characterize androgen receptor gene (AR) amplifications...
8.
Swami U, Nussenzveig R, Haaland B, Agarwal N
Ann Transl Med
. 2019 Apr;
7(Suppl 1):S18.
PMID: 31032299
No abstract available.
9.
Sonpavde G, Agarwal N, Pond G, Nagy R, Nussenzveig R, Hahn A, et al.
Cancer
. 2019 Jan;
125(9):1459-1469.
PMID: 30620391
Background: Because cell-free DNA (cfDNA) analysis facilitates the noninvasive genomic profiling of metastatic castration-resistant prostate cancer (mCRPC), the authors evaluated the association between cfDNA alterations and outcomes and evolution with...
10.
Hahn A, Gill D, Poole A, Nussenzveig R, Wilson S, Farnham J, et al.
Mol Cancer Ther
. 2018 Dec;
18(3):726-729.
PMID: 30587554
There are many treatment options available for men with metastatic castration-resistant prostate cancer (mCRPC). Yet, biomarkers predictive of differential response to treatment are currently unavailable. A recent translational study suggested...